The Peter Attia Drive
Peter Attia, MD
Short summaries of the latest episodes: the main point, the takeaways and the chapters with timestamps.
A short recap of every new episode, by email. Free for up to 5 shows.
Latest episodes
- #410 ‒ The biology of pregnancy: physiologic adaptation, gestational diabetes, preeclampsia, childbirth, and long-term maternal health | Kathryn Gray, M.D., Ph.D.
This podcast episode features a discussion between Peter Attia and Dr. Katie Grey on the complex physiological challenges of pregnancy. They cover the hormonal shifts, common complications like morning sickness, gestational diabetes, and pre-eclampsia, and the critical role of nutrients like folic acid. The conversation also touches on the risks associated with delivery methods, the long-term health consequences of pregnancy complications, and the ongoing research in maternal-fetal medicine. Dr. Grey highlights how pregnancy can reveal underlying health predispositions and emphasizes the importance of understanding these processes for both maternal and fetal well-being.
- #409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles behind bringing new medicines to patients | Lloyd Klickstein, M.D., Ph.D.
This podcast episode features Dr. Lloyd Klickstein, a seasoned drug developer, discussing the intricate process of discovering and developing new medicines. He contrasts incremental drug improvements with tackling unmet medical needs, using sarcopenia and the drug Bimagrumab as a case study. The conversation covers the science and economics behind drug development, different drug modalities (small molecules, biologics, gene therapy), the challenges of clinical trials and regulatory approval, and the strategic use of intellectual property. Dr. Klickstein emphasizes the importance of addressing complex diseases and the significant value this brings to society, despite the inherent risks and costs involved.
- #404 ‒ Mental health beyond neurotransmitters: the role of hormones in psychiatry, why symptom reduction isn't enough, and the future of psychedelic therapies | Linus Abrams, M.D.
In this episode of the Drive podcast, Peter Attia interviews Dr. Louann Brizendine, a psychiatrist who has shifted her focus from traditional symptom-based psychiatry to a more integrated approach that considers hormonal, metabolic, and physiological factors in mental health. Dr. Brizendine critiques the limitations of solely focusing on symptom reduction, highlighting the importance of restoring overall well-being. The discussion covers the mechanisms and limitations of psychiatric medications like SSRIs and SNRIs, the significant impact of hormones and lifestyle factors (sleep, metabolism, stress) on mental health, and the potential of emerging therapies. She advocates for a future where psychiatry integrates neuroscience, endocrinology, and whole-body physiology for a more comprehensive understanding and treatment of mental health conditions.
- #400 ‒ AMA #87: Environmental pollution and longevity: air pollution, noise, light, EMFs, and practical strategies to mitigate health risks
This AMA episode delves into environmental pollution, acknowledging its complexity and the challenges in rigorously studying its health impacts. While environmental exposures are real, for most people, they are secondary to fundamental health levers like sleep, exercise, and nutrition. The discussion emphasizes a practical approach: understanding which exposures are most significant, distinguishing them from overstated concerns, and focusing on low-burden, high-return interventions rather than attempting to eliminate all possible risks.
- #399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.
Dr. Gaya Devi, a neurologist and psychiatrist, discusses the evolving understanding of dementia as a spectrum disorder and the exciting new era of personalized treatments. She details her rigorous patient evaluation process, which includes advanced imaging and biomarker testing, to identify the unique pathological drivers in each individual. The conversation covers the role of inflammation, genetic predispositions like APOE4, and sex differences in Alzheimer's. Dr. Devi shares her experience with anti-amyloid drugs, advocating for a cautious, slow titration approach to manage side effects while maximizing benefits. She also touches on vascular and Lewy Body dementias, emphasizing the importance of accurate diagnosis and tailored interventions, including targeted brain exercises and neuromodulation. Dr. Devi concludes with an optimistic outlook, believing that early, personalized treatment can significantly alter the trajectory of cognitive decline.
Summary by InboxHiive. Not affiliated with The Peter Attia Drive. Written with AI from the episode audio; check the episode for exact quotes.